Valuation: Collegium Pharmaceutical, Inc.

Market Cap 936M 803M 749M 688M 1.29B 89.43B 1.31B 8.84B 3.46B 44.85B 3.51B 3.44B 148B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 936M 803M 749M 688M 1.29B 89.43B 1.31B 8.84B 3.46B 44.85B 3.51B 3.44B 148B EV / Sales 2026 *
1.12x
EV / Sales 2027 * 1.13x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.84%
1 week+11.83%
Current month-18.79%
1 month-20.34%
3 months-14.52%
6 months-36.39%
Current year-37.93%
1 week 27.14
Extreme 27.135
29.65
1 month 25.47
Extreme 25.47
36.64
Current year 25.47
Extreme 25.47
49.31
1 year 25.47
Extreme 25.47
50.79
3 years 20.95
Extreme 20.95
50.79
5 years 14.04
Extreme 14.04
50.79
10 years 7.37
Extreme 7.37
50.79
Manager TitleAgeSince
Chief Executive Officer 51 2024-11-11
Director of Finance/CFO 50 2021-05-23
Chief Tech/Sci/R&D Officer 65 2022-03-22
Director TitleAgeSince
Chairman 69 2025-05-14
Director/Board Member 72 2014-01-31
Director/Board Member 78 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
2/10/26 Free

Chief Technology Officer

54,477 0.1723%
2/10/26 Free

EVP & General Counsel

33,980 0.1075%
2/10/26 Free

Chief Executive Officer

123,091 0.3894%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%+11.83%-23.62%+20.30% 936M
+4.46%+4.92%+82.07%+134.31% 1,141B
+0.85%+4.81%+53.77%+58.51% 659B
+2.72%+6.92%+28.99%+77.15% 470B
+1.80%+0.52%+41.20%+44.05% 366B
+1.24%+2.35%+25.99%+42.21% 302B
+2.07%+2.97%+2.27%+13.06% 254B
+4.02%+6.29%+49.67%+68.96% 239B
+1.05%-0.02%-13.96%-52.13% 207B
+2.90%+8.63%+25.11%+94.52% 183B
Average +1.81%+4.88%+27.15%+50.09% 382.19B
Weighted average by Cap. +1.53%+4.31%+47.04%+74.13%

Financials

2026 *2027 *
Net sales 837M 718M 670M 615M 1.16B 79.98B 1.18B 7.91B 3.1B 40.11B 3.14B 3.07B 133B 828M 710M 663M 609M 1.14B 79.15B 1.16B 7.83B 3.06B 39.7B 3.11B 3.04B 131B
Net income - -
Net Debt - -
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
423
Date Price Change Volume
26-08-19 $28.74 +0.84% 769,362
26-08-18 $28.50 +1.53% 800,212
26-08-17 $28.07 -0.57% 865,114
26-08-14 $28.23 +0.28% 695,329
26-08-13 $28.15 +9.53% 1,558,477
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
28.74USD
Average target price
49.60USD
Spread / Average Target
+72.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COLL Stock